Volume 30, Number 1—January 2024
Research Letter
Mycobacterium senegalense Infection in Kidney Transplant Patient with Diabetes, Memphis, Tennessee, USA
Nupur Singh
, Reeti Khare, and Shirin Mazumder
, Reeti Khare, and Shirin Mazumder
Table
Antibiotic susceptibility testing for Mycobacterium conceptionense sample from kidney transplant patient with diabetes, Memphis, Tennessee, USA*
| Antibiotic | MIC, µg/mL | Interpretation |
|---|---|---|
| Amikacin IV | <8 | S |
| Amoxicillin/clavulanate | 8/4 | NI |
| Azithromycin | <16 | NI |
| Cefepime | >32 | NI |
| Cefotaxime | >64 | NI |
| Cefoxitin | <16 | S |
| Ceftriaxone | >64 | NI |
| Ciprofloxacin | <1 | S |
| Clarithromycin | <0.25 | S |
| Clofazimine | <0.5 | NI |
| Clofazimine/amikacin† | <0.5/2 | NI |
| Doxycycline | <1 | S |
| Gentamicin | <2 | NI |
| Imipenem | <2 | S |
| Kanamycin | <8 | NI |
| Linezolid | 4 | S |
| Minocycline | <1 | NI |
| Moxifloxacin | <0.5 | S |
| Tigecycline | <0.25 | NI |
| Tobramycin | 4 | I |
| Trimethoprim/sulfamethoxazole | 1/19 | S |
*I, intermediate; NI, no Clinical Laboratory Standards Institute guidelines for this antibiotic/organism combination; S, susceptible. †Clofazimine is not available as a combined medication commercially in the United States. It is available in the National Jewish Mycobacteriology Reference Laboratory for testing purposes only.
Page created: October 31, 2023
Page updated: December 20, 2023
Page reviewed: December 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.